Medical professionals' perceptions regarding therapeutic adherence in patients with osteoporosis

被引:6
作者
Blanch, J. [1 ]
Casado, E. [2 ]
Gonzalez, J. [3 ]
Valdes, C. [4 ]
Ruiz-Baena, J. [5 ]
Palomino, R. [5 ]
Nogues, X. [6 ,7 ]
机构
[1] Inst Hosp del Mar Invest Med IMIM, Serv Reumatol, Parque Salud Mar, Barcelona, Spain
[2] Hosp Univ Parque Tauli, Serv Reumatol, Barcelona, Spain
[3] Complejo Hosp Univ Granada, Unidad Gest Clin Reumatol, Granada, Spain
[4] Serv Madrileno Salud SERMAS, Direcc Asistencial Norte, Ctr Salud Fuencarral, Med Familiar & Comunitaria, Madrid, Spain
[5] GOC Networking, Barcelona, Spain
[6] Univ Autonoma Barcelona, Dept Med Interna, Parque Salud Mar, Barcelona, Spain
[7] Inst Salud Carlos III FEDER, Red Temat Invest Cooperat Envejecimiento & Fragil, Inst Hosp del Mar Invest Med IMIM, Barcelona, Spain
关键词
osteoporosis; surveys; bisphosphonates; therapeutic adherence; opinion;
D O I
10.4321/S1889-836X2016000100003
中图分类号
R5 [内科学];
学科分类号
1002 [临床医学]; 100201 [内科学];
摘要
Introduction: Adherence to oral treatment of patients with osteoporosis is low, with a high dropout rate in the first year. The most noteworthy result is the lack of therapeutic response. Objective: To ascertain the perception of physicians working with osteoporotic patients regarding adherence of these patients. Methods: Cross-sectional study conducted by opinion survey aimed at primary care physicians and specialists involved in osteoporosis treatment. Participants were selected by purposive sampling. Results: The questionnaire was answered by 235 specialists encompassing rheumatology (54.5%), orthopedics (10.6%) and primary care (18.7%). In 43.8% of participants, more than 25% of patients sometimes forget to take their treatment. According to 34.9%, more than 75% of patients are aware of treatment. Side effects and management complexity are the majority reasons that lead to a change in medication, mean value of 7.94 +/- 2.06 6 +/- 2.01 points respectively on a 0-10 scale. Conclusions: Overall, medical specialists attributed low adherence to side effects, polypharmacy and lack of communication between professionals. Dosage and space use of soluble dosage forms may be options to facilitate patient adherence to treatment with oral bisphosphonates. Improved education concerning the importance of the disease or increased patient monitoring could foster adherence.
引用
收藏
页码:15 / 23
页数:9
相关论文
共 40 条
[1]
[Anonymous], 2001, South Med J, V94, P569
[2]
Communication between primary care and physician specialist: Is it improving [J].
Biagetti, B. ;
Aulinas, A. ;
Dalama, B. ;
Nogues, R. ;
Zafon, C. ;
Mesa, J. .
REVISTA DE CALIDAD ASISTENCIAL, 2015, 30 (04) :175-181
[3]
Burge R, 2007, J BONE MINER RES, V22, P465, DOI [10.1359/jbmr.061113, 10.1359/JBMR.061113]
[4]
Measuring and improving adherence to osteoporosis pharmacotherapy [J].
Cadarette, Suzanne M. ;
Burden, Andrea M. .
CURRENT OPINION IN RHEUMATOLOGY, 2010, 22 (04) :397-403
[5]
Factors associated with adherence and persistence to bisphosphonate therapy in osteoporosis: a cross-sectional survey [J].
Carr, A. J. ;
Thompson, P. W. ;
Cooper, C. .
OSTEOPOROSIS INTERNATIONAL, 2006, 17 (11) :1638-1644
[6]
Clark EM, 2015, OSTEOPOROS INT
[7]
Costa i Pages J, 2014, B INFORM TERAPEUTICA, V25, P29
[8]
A Markov Model Simulation of the Impact of Treatment Persistence in Postmenopausal Osteoporosis [J].
Cotte, Francois-Emery ;
Fautrel, Bruno ;
De Pouvourville, Gerard .
MEDICAL DECISION MAKING, 2009, 29 (01) :125-139
[9]
A systematic review of persistence and compliance with bisphosphonates for osteoporosis [J].
Cramer, J. A. ;
Gold, D. T. ;
Silverman, S. L. ;
Lewiecki, E. M. .
OSTEOPOROSIS INTERNATIONAL, 2007, 18 (08) :1023-1031
[10]
Danese MD, 2009, J BONE MINER RES, V24, P1819, DOI [10.1359/JBMR.090506, 10.1359/jbmr.090506]